跳至主要内容
临床试验/ISRCTN54960762
ISRCTN54960762已完成不适用

IMIT-1: Lowering the Incidence of vascular complications with Metformin in patients with Impaired glucose Tolerance and a recent transient ischaemic attack or minor ischaemic stroke: a phase II randomised, controlled trial

Erasmus Medical Centre (The Netherlands)0 个研究点目标入组 40 人开始时间: 2007年4月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Men or women 18 years and over
  • 2. TIA/minor ischaemic stroke (modified Rankin Score three or less) within six months
  • 3. Impaired fasting glucose (fasting glucose level of 5.6 to 6.9 mmol/L) and/or impaired glucose tolerance (two-hour post-load glucose level of 7.8 to 11.0 mmol/L)
  • 4. Informed consent

排除标准

  • 1. Known or newly diagnosed diabetes mellitus
  • 2. Contraindication for metformin:
  • 2.1. Renal impairment (serum creatinine greater than 135 micromol/L for men, and greater than 110 micromol/L for women)
  • 2.2. Hepatic disease (liver enzymes increased twice the upper limit of normal)
  • 2.3. A past history of lactic acidosis
  • 2.4. Cardiac failure requiring pharmacological therapy
  • 2.5. Chronic hypoxic lung disease
  • 2.6. Pregnancy
  • 2.7. Breast feeding
  • 3. Severe comorbidity interfering with follow-up

研究者

发起方
Erasmus Medical Centre (The Netherlands)

相似试验